1. Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS). (April 2017) Authors: Stein, E.M.; Fathi, A.T.; DiNardo, C.D.; Pollyea, D.A.; Swords, R.T.; Roboz, G.J.; Collins, R.; Sekeres, M.A.; Stone, R.M.; Attar, E.C.; Tosolini, A.; Xu, Q.; Amatangelo, M.; Gupta, I.; Knight, R.D.; de Botton, S.; Tallman, M.S.; Kantarjian, H.M. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗